We’re pleased to inform you that our Comprehensive Panel with Analyte Assurance™, along with the referenced panels below, will be updated for all orders effective September 29, 2025. The following analytes will be added:

• 5F-ADB Butanoic Acid Metabolite – Confirmed via Synthetic Cannabinoids Panel
• 7-Hydroxymitragynine – Confirmed via Novel Emerging Compounds Panel
• MDPHP – Confirmed via Novel Emerging Compounds Panel
• BTMPS – Confirmed via Novel Emerging Compounds Panel
• Diphenidine – Confirmed via Novel Emerging Compounds Panel

As with all components of Analyte Assurance™, if any of these analytes screen positive, our Lab Client Support team will contact you directly to determine whether confirmatory testing is desired.

At Axis Forensic Toxicology, we are committed to evolving with the needs of our clients and the ever-changing landscape of emerging substances. These additions reflect our proactive approach to ensuring you receive the most comprehensive and reliable testing services available.

If you have any questions or would like more information regarding this update, please don’t hesitate to reach out to us at [email protected]. Our team is always ready to assist.

Thank you for your continued partnership and trust in Axis. We look forward to continuing to support your work with the highest quality service and testing solutions.

Sincerely,

Matt Zollman
Director of Operations & Product Management